Summary:
Successful hematopoietic progenitor cell transplantation requires rapid and complete transfer of the donor hematopoietic and immune systems to the host. Whereas the uncontrolled transfer of a nontolerant donor immune system results in GVHD in many cases, strategies which diminish GVHD also diminish immune reconstitution. Thus, the reliable, rapid and safe transfer of immunity from donor to host remains a major challenge for the field. Advances in the understanding of the biology of immune reconstitution have elucidated that thymic-dependent immune reconstitution can restore global immunity, but is especially vulnerable to toxicities associated with transplant. Alternatively, homeostatic peripheral expansion can be exploited for targeted immunity toward pathogens and tumors, but is difficult to manipulate without exacerbating GVHD risk. New translatable strategies are needed to safely augment one or both of these pathways in the setting of allogeneic hematopoietic progenitor cell transplantation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ochs L, Shu XO, Miller J et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood 1995; 86: 3979–3986.
Roy V, Ochs L, Weisdorf D . Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis. Leuk Lymphoma 1997; 26: 1–15.
Storek J, Espino G, Dawson MA et al. Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. Blood 2000; 96: 3290–3293.
Chen CS, Boeckh M, Seidel K et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 515–522.
Storek J . B-cell immunity after allogeneic hematopoietic cell transplantation. Cytotherapy 2002; 4: 423–424.
Storek J, Viganego F, Dawson MA et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood 2003; 101: 3319–3324.
Miller RA, Stutman O . T cell repopulation from functionally restricted splenic progenitors: 10 000-fold expansion documented by using limiting dilution analyses. J Immunol 1984; 133: 2925–2932.
Stutman O . Postthymic T-cell development. Immunol Rev 1986; 91: 159–194.
Mackall CL, Gress RE . Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev 1997; 157: 61–72.
Fry TJ, Christensen BL, Komschlies KL et al. Interleukin-7 restores immunity in athymic T-cell-depleted hosts. Blood 2001; 97: 1525–1533.
Hakim FT, Cepeda R, Kaimei S et al. Constraints on CD4 recovery post chemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 1997; 90: 3789–3798.
Mackall CL, Bare CV, Titus JA et al. Thymic-independent T cell regeneration occurs via antigen driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 1996; 156: 4609–4616.
Goldrath AW, Bevan MJ . Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 1999; 11: 183–190.
Goldrath AW, Bevan MJ . Selecting and maintaining a diverse T-cell repertoire. Nature 1999; 402: 255–262.
Weinberg K, Blazar BR, Wagner JE et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. Blood 2001; 97: 1458–1466.
Douek DC, Vescio RA, Betts MR et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet 2000; 355: 1875–1881.
Roux E, Helg C, Fumont-Girard F et al. Analysis of T cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996; 87: 3984–3992.
Zinkernagel RM, Althage A, Callahan G, Welsh RM . On the immunocompetence of H-2 incompatible irradiation bone marrow chimeras. J Immunol 1980; 124: 2356–2365.
Ghayur T, Seemayer TA, Xenocostas A, Lapp WS . Complete sequential regeneration of graft-vs-host induced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs-host disease. Am J Pathol 1988; 133: 39–46.
Fukushi N, Arase H, Wang B et al. Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance. PNAS 1990; 87: 6301–6305.
Brochu S, Rioux-Masse B, Roy J et al. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versus-host disease. Blood 1999; 94: 390–400.
Porter DL, Collins RH, Hardy C et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214–1221.
Dazzi F, Szydlo RM, Goldman JM . Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol 1999; 27: 1477–1486.
Helg C, Starobinski M, Jeannet M, Chapuis B . Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 1998; 29: 301–313.
Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850–854.
Molldrem JJ, Lee PP, Wang C et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018–1023.
Min D, Taylor PA, Panoskaltsis-Mortari A et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 2002; 99: 4592–4600.
Puel A, Ziegler SF, Buckley RH, Leonard WJ . Defective IL7R expression in T(−)B(+)NK(+) severe combined immunodeficiency. Nat Genet 1998; 20: 394–397.
Fry TJ, Moniuszko M, Creekmore S et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003; 101: 2294–2299.
Sinha ML, Fry TJ, Fowler DH et al. Interleukin 7 worsens graft-versus-host disease. Blood 2002; 100: 2642–2649.
Fry TJ, Sinha M, Milliron M et al. Flt 3 ligand enhances thymic-dependent and thymic-independent immune reconstitution. Blood 2004; 104: 2794–2800.
Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100.
Napolitano LA, Lo JC, Gotway MB et al. Increased thymic mass and circulating naive CD4T cells in HIV-1-infected adults treated with growth hormone. AIDS 2002; 16: 1103–1111.
Olsen NJ, Kovacs WJ . Effects of androgens on T and B lymphocyte development. Immunol Res 2001; 23: 281–288.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fry, T., Mackall, C. Immune reconstitution following hematopoietic progenitor cell transplantation: challenges for the future. Bone Marrow Transplant 35 (Suppl 1), S53–S57 (2005). https://doi.org/10.1038/sj.bmt.1704848
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704848
Keywords
This article is cited by
-
Early T-cell reconstitution predicts risk of EBV reactivation after allogeneic hematopoietic stem cell transplantation
Clinical and Experimental Medicine (2024)
-
CMV serostatus and T-cell repertoire diversity 5 years after allogeneic hematopoietic stem cell transplantation
Leukemia (2023)
-
Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus
Current Hematologic Malignancy Reports (2019)
-
Acute myeloid leukemia targets for bispecific antibodies
Blood Cancer Journal (2017)
-
Treatment with Low Doses of Polyclonal Immunoglobulin Improves B Cell Function During Immune Reconstitution in a Murine Model
Journal of Clinical Immunology (2013)